Biotech Values

[mcbio]

On FoB’s #3-#6, I fully expect MNTA to opt in for the 30% cost-and-profit share.

I hope so. Taking together the potential for max royalty of about 20% on the first two FoBs and the potential for the 30% cost-and-profit share on FoBs #3-#6 makes the financial terms of this deal reasonable for me. While I would have preferred a larger up-front, it's the royalties/profit share that are of most importance and I'm now more comfy with those terms.